Why Connected AI Platforms Are Becoming the Foundation of Modern Drug Discovery

Artificial intelligence has reached an important turning point in life sciences.

Over the past few years, headlines have focused on AI models that can predict protein structures, generate novel molecules, or identify promising drug candidates in a fraction of the time required by traditional methods. Those breakthroughs have attracted billions of dollars in investment and created a new generation of AI-native biotechnology companies.

Yet one of the biggest challenges facing pharmaceutical companies today has little to do with the models themselves.

The problem is data.

A recent example illustrates why. Dassault Systèmes announced its planned acquisition of ArisGlobal, a leader in regulatory and pharmacovigilance software. On the surface, the deal expands Dassault’s enterprise software portfolio. Viewed more broadly, it reflects a larger shift occurring across the life sciences industry.

Companies are no longer investing only in AI applications. They are investing in connected platforms capable of bringing together research, clinical development, regulatory affairs, manufacturing, and commercial operations.

That may ultimately prove more valuable than any single AI model.

The First Wave of AI Focused on Discovery

The first generation of AI in life sciences concentrated on one objective: accelerating drug discovery.

Machine learning models helped researchers identify new therapeutic targets, optimize lead compounds, predict molecular properties, and reduce the number of expensive laboratory experiments.

This approach produced an entirely new category of biotechnology companies.

Organizations such as GenBio AI, Isomorphic Labs, Recursion, Insilico Medicine, Generate:Biomedicines, Absci, and EvolutionaryScale are applying foundation models and large-scale machine learning to biological research. Although each company has a different scientific strategy, they share a common goal of making drug discovery faster, more predictable, and increasingly data driven.

Their work has demonstrated that AI can contribute meaningful insights long before a molecule reaches clinical trials.

But discovery is only one chapter in the pharmaceutical lifecycle.

The Real Challenge Begins After Discovery

Finding a promising molecule is only the beginning.

Drug candidates must move through years of preclinical research, clinical trials, regulatory review, manufacturing, pharmacovigilance, and commercial distribution.

Each stage generates enormous volumes of scientific and operational data.

Unfortunately, much of that data remains fragmented.

Research scientists may work in electronic laboratory notebooks.

Clinical teams rely on clinical trial management systems.

Regulatory affairs manage submission documents using entirely different platforms.

Manufacturing facilities operate separate quality systems.

Drug safety teams collect adverse event data using specialized pharmacovigilance software.

When information remains isolated across dozens of applications, AI struggles to produce meaningful enterprise-wide insights.

The challenge is no longer building smarter models.

It is connecting better data.

Platform Thinking Is Replacing Point Solutions

This helps explain why enterprise software companies are expanding aggressively across the pharmaceutical technology stack.

Dassault Systèmes’ acquisition of ArisGlobal follows years of investment in Medidata and its broader 3DEXPERIENCE platform.

Veeva Systems continues expanding beyond customer relationship management into clinical, quality, and regulatory applications.

IQVIA combines clinical research, healthcare analytics, and real-world evidence.

Benchling has become a foundational platform for scientific data management across biotechnology companies.

Oracle Health continues integrating healthcare data and cloud infrastructure.

Each company is pursuing the same long-term objective.

Create a connected environment where AI can operate across the entire product lifecycle rather than inside isolated applications.

That strategy mirrors what happened in enterprise software over the past two decades, where integrated platforms gradually replaced disconnected point solutions.

Foundation Models Need Enterprise Data

Much of the public conversation around AI focuses on increasingly capable foundation models.

Those models are important.

However, their value depends entirely on the quality of the information available to them.

Life sciences presents a unique challenge because biological, clinical, manufacturing, and regulatory datasets often exist in completely different formats.

Connecting those datasets requires more than powerful models.

It requires common data standards, governance, interoperability, and secure infrastructure.

This is where enterprise platforms become strategically important.

Companies such as GenBio AI and EvolutionaryScale are developing biological foundation models capable of understanding DNA, RNA, proteins, and cellular systems at unprecedented scale.

At the same time, enterprise platforms from Benchling, Veeva Systems, IQVIA, and Medidata provide the structured scientific information those models need to generate useful outputs inside regulated environments.

Neither layer succeeds without the other.

AI Is Expanding Beyond Drug Discovery

Drug discovery remains the most visible AI application in life sciences, but it is no longer the fastest-growing opportunity.

Organizations are beginning to deploy AI throughout the pharmaceutical value chain.

Clinical operations teams use AI to identify trial participants and predict enrollment challenges.

Regulatory affairs teams explore copilots that summarize guidance documents and prepare submission packages.

Manufacturing organizations apply machine learning to monitor production quality.

Commercial teams analyze healthcare data to improve market access and physician engagement.

Companies including Tempus AI and Owkin demonstrate how multimodal AI can combine molecular information with clinical data to support precision medicine and translational research.

Meanwhile, NVIDIA BioNeMo, Microsoft Azure, AWS, and Google Cloud are providing specialized infrastructure that enables pharmaceutical organizations to develop and deploy increasingly sophisticated AI applications.

The ecosystem is becoming much broader than drug discovery alone.

Why Consolidation Is Accelerating

Technology markets often move through predictable stages.

Innovation begins with specialized startups.

As adoption grows, customers demand integration.

Eventually, larger platforms emerge through acquisitions and partnerships.

Life sciences appears to be entering that third phase.

Pharmaceutical companies increasingly prefer fewer technology vendors capable of supporting multiple workflows.

They want research data connected to clinical operations.

Clinical systems connected to regulatory submissions.

Manufacturing connected to quality management.

Commercial insights connected to real-world evidence.

The objective is not simply operational efficiency.

Connected data enables AI systems to reason across the entire organization rather than within isolated departments.

That creates opportunities that standalone applications cannot easily deliver.

What Pharmaceutical Leaders Should Prioritize

Executives evaluating AI strategies should begin with infrastructure rather than algorithms.

Key questions include:

Can research, clinical, regulatory, and manufacturing data be accessed through common standards?
Are scientific datasets governed consistently?
Can AI applications operate across departments?
Does the organization have a long-term platform strategy?
Can new foundation models be adopted without rebuilding existing systems?

These decisions will likely determine the pace of AI adoption more than choosing a particular model provider.

The organizations generating the greatest value from AI over the next decade may not have access to the most advanced models.

They will have the strongest data foundations.

Looking Ahead

Life sciences is entering a new phase of AI adoption.

The first chapter focused on proving that machine learning could accelerate scientific discovery.

The next chapter will focus on integrating those discoveries into enterprise workflows that span the entire pharmaceutical lifecycle.

AI-native innovators such as GenBio AI, Isomorphic Labs, Recursion, Insilico Medicine, Generate:Biomedicines, EvolutionaryScale, and Absci will continue advancing biological foundation models and computational drug discovery.

At the same time, enterprise software providers including Dassault Systèmes, Veeva Systems, IQVIA, Benchling, Oracle Health, and Medidata are building the platforms that allow those scientific advances to operate at global scale.

The companies that succeed will combine both capabilities.

Powerful AI models.

Connected enterprise data.

Integrated workflows.

That combination is likely to define the next decade of innovation in pharmaceutical research and development.

Key Takeaways

AI in life sciences is evolving from standalone discovery tools to connected enterprise platforms.
Data integration has become one of the largest barriers to scaling AI across pharmaceutical organizations.
GenBio AI, Isomorphic Labs, Recursion, Insilico Medicine, Generate:Biomedicines, and EvolutionaryScale represent the next generation of AI-native biotechnology companies.
Enterprise software vendors are expanding AI across research, clinical development, regulatory affairs, manufacturing, and commercial operations.
Organizations that invest in interoperable data platforms today will be better positioned to adopt future AI innovations.

What to Watch Next

Continued consolidation among life sciences software providers.
Greater enterprise adoption of biological foundation models.
More partnerships between AI-native biotech startups and enterprise software vendors.
Expansion of AI copilots for clinical, regulatory, and manufacturing teams.
Industry-wide efforts to improve scientific data interoperability and governance.